Compare Abbott Laboratories (ABT) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Zeta Global Holdings Corp — how do they compare? Abbott Laboratories trades at $95.67 (market cap $166.94B), while Zeta Global Holdings Corp trades at $21.33 (market cap $5.45B). The key difference: Abbott Laboratories is far larger — about 30.6× Zeta Global Holdings Corp's market cap, and Abbott Laboratories pays a 2.63% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals.
| ABT | ZETA | |
|---|---|---|
Market Cap | $166.94B | $5.45B |
Sector | Health | Technology |
52-Week High | $136.62 | $25.24 |
52-Week Low | $82.57 | $14.00 |
Enterprise Value | $193.69B | $5.36B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ZETA trades at $21.82, up 5.46% over the past 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $27.50. Recent earnings beats and a strategic AI partnership with Palantir highlight strong operational momentum, though negative net income and cash flow remain concerns. The stock shows robust revenue growth and high gross margins, supported by positive media coverage and institutional interest.
The outlook for ZETA is cautiously optimistic, driven by AI integration and consistent earnings outperformance. Key risks include persistent unprofitability and competitive pressures in the marketing technology sector. Investors should weigh the high valuation multiples against growth potential, with analyst sentiment strongly favoring buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
